ABBV vs HSTM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
HSTM presents a contradictory profile: while the Piotroski F-Score of 7/9 indicates strong fundamental health and a clean balance sheet, the valuation is severely disconnected from intrinsic reality. The stock trades at $19.88, significantly above both its Graham Number ($12.82) and its growth-based intrinsic value ($4.27). This valuation gap is exacerbated by a collapse in earnings growth (-46.5% YoY) and a completely bearish technical trend (0/100). Despite low debt, the combination of crashing profitability and insider selling suggests a value trap scenario.
Compare Another Pair
Related Comparisons
ABBV vs HSTM: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and HealthStream, Inc. (HSTM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.